Everolimus for colorectal cancer with a specific gene marker
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called everolimus for people with advanced colorectal cancer that has a specific change in a gene called CDK12. It aims to see if this drug can slow down the cancer when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old and have metastatic colorectal cancer.
- Your cancer has a specific gene marker called CDK12 deficiency, which can be confirmed by a tissue test.
- You have already tried standard treatments like oxaliplatin, fluoropyrimidine, irinotecan, or immunotherapy (if your tumor is MSI-high), and your cancer has continued to grow.
- You have at least one measurable tumor that can be seen on a CT scan.
- You are generally in good health, with adequate organ function and no serious heart, lung, or active infections.
- You have recovered from previous treatment side effects to mild or no symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs—everolimus, which may slow cancer growth, and a PD-1 inhibitor, which helps the immune system fight cancer—for people with advanced colorectal cancer that has progressed after standard treatments. The goal is to see if the combination can shrink or control the cancer.
This trial studies a drug called everolimus given after liver cancer surgery to see if it helps prevent the cancer from returning. Everolimus is a pill that may help stop cancer cell growth.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
This trial tests a drug called everolimus in women with hormone receptor-positive metastatic breast cancer who have already tried alpelisib (a PI3K inhibitor) combined with hormone therapy. The goal is to see if this next treatment can help control cancer growth.
This study tests a drug called everolimus to see if it helps treat vascular malformations (abnormal clusters of blood vessels). It is for adults aged 18 to 65 who have been diagnosed by MRI and are able to take oral medication.
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.